Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Trader J's Inner Circle -- Ignore unavailable to you. Want to Upgrade?

To: Triffin who wrote (15293)	5/26/1999 3:23:00 PM
From: LTK007	Read Replies (2) \| Respond to of 56537

This bit from CBS Market report on Compumed yesterday made me take a flyer--one I found out Paine Webber and other analysts took note and found this Osteogram device was funded by the U.S Govt. and Merck--so what the hell take a chance " Greater power to detect deteriorating bone mass is good news for makers of osteoporosis drugs, analysts said. Between 25 million and 30 million people in the U.S. have osteoporosis, according to PaineWebber. About 80 percent of them are women and only about 5 percent will be diagnosed before breaking a bone, said Jeff Chaffkin, an analyst at PaineWebber. Merck (MRK: news, msgs) makes the leading osteoporosis drug, Fosamax, which is one of its bigger products, Chaffkin said. In 1998 sales of Fosamax were $775 million worldwide, he said. About $505 million, or 70 percent of those sales were in the U.S. Merck was a sponsor along the U.S. Public Health Service and the Hawaii Osteoporosis Foundation of a three-year study of the OsteoGram."